Saudi Arabia Point-of-Care Glucose Testing Market By Product Type (Lancing Devices and Strips, Blood-Glucose Meter), By Application (Type-1 Diabetes, Type-2 Diabetes), By End User (Hospitals and Clinics, Home Care Settings, Others): Opportunity Analysis a
Description
Saudi Arabia Point-of-Care Glucose Testing Market By Product Type (Lancing Devices and Strips, Blood-Glucose Meter), By Application (Type-1 Diabetes, Type-2 Diabetes), By End User (Hospitals and Clinics, Home Care Settings, Others): Opportunity Analysis and Industry Forecast, 2023-2032
In a nation where diabetes is alarmingly prevalent, point-of-care glucose testing plays a pivotal role in managing the condition. The Saudi Arabia point-of-care glucose testing market is majorly driven by rise in incidence of diabetes in the country. Moreover, alarming increase in prevalence of both type-1 and type-2 diabetes acts as a prominent factor that augments the demand for glucose monitoring tools, thus contributing toward the growth of the point-of-care glucose testing market. Moreover, technological advancements in the field of glucose monitoring have revolutionized the way patients manage their conditions. The introduction of sophisticated lancing devices and blood glucose meters has not only made glucose testing more accessible but also more accurate. In addition, the inclination toward preventive care is another driving force of the Saudi Arabia point-of-care glucose testing market. Hospitals, clinics, and home care settings have embraced point-of-care glucose testing as a critical tool in early diagnosis and patient management. As a result, the market is witnessing a steady flow of investment and adoption. However, the cost associated with high-end glucose monitoring devices restrains the market growth. Although advanced technology has improved accuracy, it has pushed the prices upwards, making it a challenge for patients with limited financial resources to access these tools. Moreover, lack of awareness regarding diabetes and glucose testing among the general population limits the growth of the market.
On the contrary, the convenience and efficiency of at-home glucose testing are enticing more patients to take charge of their health. This shift serves as a potential opportunity for the market growth in the coming years. As the demand for accurate and non-invasive glucose monitoring solutions continues to rise, it will inevitably spur the growth of new, more user-friendly technologies, which is anticipated to propel the market growth. Government initiatives and regulations further pave the way for growth. With a commitment to improving healthcare infrastructure and patient outcomes, Saudi Arabia is likely to witness an increase in investments in this sector. This will create new avenues for market expansion. The Saudi Arabia point-of-care glucose testing market is segmented into product type, application, and end user. On the basis of product type, the market is fragmented into lancing devices & strips and blood glucose meters. Lancing devices and strips being popular for their ease of use and accessibility. Blood glucose meters, on the other hand, are favored for their precision. Depending on application, it is bifurcated into type-1 diabetes and type-2 diabetes. Type-1 diabetes patients often require more intensive monitoring, as their condition is insulin-dependent. In contrast, type-2 diabetes, while more common, may necessitate less frequent testing. This distinction underscores the importance of catering to the specific needs of each group. By end user, it is categorized into hospitals & clinics, home care settings, and others. Hospitals & clinics often provide immediate care, whereas home care settings offer long-term monitoring and patient empowerment.
The prominent players operating in the Saudi Arabia point-of-care glucose testing market are Roche Diagnostics, Abbott Laboratories, Siemens Healthineers, Nova Biomedical, Bionime, Sinocare, Medtronic, LifeScan, ACON Laboratories, Ypsomed Holding AG New product development is a critical aspect, with manufacturers investing in R&D to introduce more user-friendly and cost-effective solutions. Consumer and end-user perceptions are heavily influenced by the ease of use, accuracy, and reliability of glucose testing devices. Patients seek tools that integrate seamlessly into their daily routines, minimizing disruption and discomfort. Healthcare providers, on the other hand, value devices that provide precise data to inform treatment decisions. The Porter's five forces analysis reveals a complex landscape of competitive rivalry, bargaining power of suppliers, bargaining power of buyers, threat of new entrants, and threat of substitute products. Competitive rivalry is intensified as more manufacturers enter the market, striving to capture a share of the growing demand for glucose testing tools. The diversity in product types and applications further amplifies competition. Suppliers of glucose monitoring devices may hold significant bargaining power, especially those producing cutting-edge technology. As demand surges, suppliers have the leverage to dictate terms and prices.
Buyers, predominantly hospitals and clinics, have some bargaining power due to the wide range of product options available. They can choose from various manufacturers, impacting prices and terms. The threat of new entrants is influenced by the barriers to entry, including regulatory requirements and the need for substantial research and development investments. However, the demand for innovative solutions continues to attract potential newcomers. The threat of substitute products primarily pertains to alternative glucose monitoring methods, such as continuous glucose monitoring (CGM) systems. The choice between traditional Point-of-Care testing and CGM systems depends on individual patient needs and preferences. A SWOT analysis further unveils the internal strengths and weaknesses and the external opportunities and threats in the Saudi Arabia point-of-care glucose testing market. Strengths include the market's adaptability and responsiveness to technological advancements. This agility ensures that patients have access to cutting-edge solutions for disease management.
Weaknesses revolve around the cost of advanced glucose monitoring devices and the need for better awareness among the population about the importance of regular testing. Opportunities are abundant, driven by the rising diabetes prevalence and the government's commitment to enhancing healthcare infrastructure. Innovations in product development and the growth of home care settings are key opportunities. Threats include the intense competition among manufacturers, as well as the threat of substitute products like CGM systems. Maintaining market share and relevance amidst these challenges is a critical consideration. In conclusion, as Saudi Arabia grapples with the growing burden of diabetes, the point-of-care glucose testing market continues to evolve, offering hope and progress in the quest for improved patient care and disease management.
Key Benefits For Stakeholders
Enable informed decision-making process and offer market analysis based on current market situation and estimated future trends.
Analyze the key strategies adopted by major market players in Saudi Arabia point-of-care glucose testing market.
Assess and rank the top factors that are expected to affect the growth of Saudi Arabia point-of-care glucose testing market.
Top player positioning provides a clear understanding of the present position of market players.
Detailed analysis of the Saudi Arabia point-of-care glucose testing market segmentation assists to determine the prevailing market opportunities.
Identify key investment pockets for various offerings in the market.
Product Benchmarking / Product specification and applications
Upcoming/New Entrant by Regions
New Product Development/ Product Matrix of Key Players
Patient/epidemiology data at country, region, global level
Additional company profiles with specific to client's interest
Additional country or region analysis- market size and forecast
Expanded list for Company Profiles
Historic market data
SWOT Analysis
Key Market Segments
By Product Type
Lancing Devices and Strips
Blood-Glucose Meter
Type
Lifescan OneTouch Ultra and Lifescan OneTouch Verio
Accu-Chek Aviva Plus and Accuchek
Freestyle Lite and Freestyle Precission Neo
Contour Next
Others
By Application
Type-1 Diabetes
Type-2 Diabetes
By End User
Hospitals and Clinics
Home Care Settings
Others
Key Market Players
Roche Diagnostics
Abbott Laboratories
Siemens Healthineers
Nova Biomedical
Bionime
Sinocare
Medtronic
LifeScan
ACON Laboratories
Ypsomed Holding AG
Please Note: It will take 7-10 business days to complete the report upon order confirmation.
Table of Contents
80 Pages
- CHAPTER 1: INTRODUCTION
- 1.1. Report Description
- 1.2. Key Market Segments
- 1.3. Key Benefits to the Stakeholders
- 1.4. Research Methodology
- 1.4.1. Primary Research
- 1.4.2. Secondary Research
- 1.4.3. Analyst Tools and Models
- CHAPTER 2: EXECUTIVE SUMMARY
- 2.1. CXO Perspective
- CHAPTER 3: MARKET OVERVIEW
- 3.1. Market Definition and Scope
- 3.2. Key Findings
- 3.2.1. Top Impacting Factors
- 3.2.2. Top Investment Pockets
- 3.3. Porter’s Five Forces Analysis
- 3.4. Market Dynamics
- 3.4.1. Drivers
- 3.4.2. Restraints
- 3.4.3. Opportunities
- 3.5. COVID-19 Impact Analysis on the market
- CHAPTER 4: SAUDI ARABIA POINT-OF-CARE GLUCOSE TESTING MARKET, BY PRODUCT TYPE
- 4.1. Overview
- 4.1.1. Market Size and Forecast, By Product Type
- 4.2. Lancing Devices and Strips
- 4.3. Blood-Glucose Meter
- CHAPTER 5: SAUDI ARABIA POINT-OF-CARE GLUCOSE TESTING MARKET, BY APPLICATION
- 5.1. Overview
- 5.1.1. Market Size and Forecast, By Application
- 5.2. Type-1 Diabetes
- 5.3. Type-2 Diabetes
- CHAPTER 6: SAUDI ARABIA POINT-OF-CARE GLUCOSE TESTING MARKET, BY END USER
- 6.1. Overview
- 6.1.1. Market Size and Forecast, By End User
- 6.2. Hospitals and Clinics
- 6.3. Home Care Settings
- 6.4. Others
- CHAPTER 7: COMPETITIVE LANDSCAPE
- 7.1. Introduction
- 7.2. Top winning strategies
- 7.3. Product Mapping of Top 10 Player
- 7.4. Competitive Dashboard
- 7.5. Competitive Heatmap
- 7.6. Top player positioning, 2022
- CHAPTER 8: COMPANY PROFILES
- 8.1. Roche Diagnostics
- 8.1.1. Company overview
- 8.1.2. Key Executives
- 8.1.3. Company snapshot
- 8.1.4. Operating business segments
- 8.1.5. Product portfolio
- 8.1.6. Business performance
- 8.1.7. Key strategic moves and developments
- 8.2. Abbott Laboratories
- 8.2.1. Company overview
- 8.2.2. Key Executives
- 8.2.3. Company snapshot
- 8.2.4. Operating business segments
- 8.2.5. Product portfolio
- 8.2.6. Business performance
- 8.2.7. Key strategic moves and developments
- 8.3. Siemens Healthineers
- 8.3.1. Company overview
- 8.3.2. Key Executives
- 8.3.3. Company snapshot
- 8.3.4. Operating business segments
- 8.3.5. Product portfolio
- 8.3.6. Business performance
- 8.3.7. Key strategic moves and developments
- 8.4. Nova Biomedical
- 8.4.1. Company overview
- 8.4.2. Key Executives
- 8.4.3. Company snapshot
- 8.4.4. Operating business segments
- 8.4.5. Product portfolio
- 8.4.6. Business performance
- 8.4.7. Key strategic moves and developments
- 8.5. Bionime
- 8.5.1. Company overview
- 8.5.2. Key Executives
- 8.5.3. Company snapshot
- 8.5.4. Operating business segments
- 8.5.5. Product portfolio
- 8.5.6. Business performance
- 8.5.7. Key strategic moves and developments
- 8.6. Sinocare
- 8.6.1. Company overview
- 8.6.2. Key Executives
- 8.6.3. Company snapshot
- 8.6.4. Operating business segments
- 8.6.5. Product portfolio
- 8.6.6. Business performance
- 8.6.7. Key strategic moves and developments
- 8.7. Medtronic
- 8.7.1. Company overview
- 8.7.2. Key Executives
- 8.7.3. Company snapshot
- 8.7.4. Operating business segments
- 8.7.5. Product portfolio
- 8.7.6. Business performance
- 8.7.7. Key strategic moves and developments
- 8.8. LifeScan
- 8.8.1. Company overview
- 8.8.2. Key Executives
- 8.8.3. Company snapshot
- 8.8.4. Operating business segments
- 8.8.5. Product portfolio
- 8.8.6. Business performance
- 8.8.7. Key strategic moves and developments
- 8.9. ACON Laboratories
- 8.9.1. Company overview
- 8.9.2. Key Executives
- 8.9.3. Company snapshot
- 8.9.4. Operating business segments
- 8.9.5. Product portfolio
- 8.9.6. Business performance
- 8.9.7. Key strategic moves and developments
- 8.10. Ypsomed Holding AG
- 8.10.1. Company overview
- 8.10.2. Key Executives
- 8.10.3. Company snapshot
- 8.10.4. Operating business segments
- 8.10.5. Product portfolio
- 8.10.6. Business performance
- 8.10.7. Key strategic moves and developments
- LIST OF TABLES
- TABLE 01. SAUDI ARABIA POINT-OF-CARE GLUCOSE TESTING MARKET, BY PRODUCT TYPE, 2022-2032 ($MILLION)
- TABLE 02. SAUDI ARABIA POINT-OF-CARE GLUCOSE TESTING MARKET, BY APPLICATION, 2022-2032 ($MILLION)
- TABLE 03. SAUDI ARABIA POINT-OF-CARE GLUCOSE TESTING MARKET, BY END USER, 2022-2032 ($MILLION)
- TABLE 04. ROCHE DIAGNOSTICS: KEY EXECUTIVES
- TABLE 05. ROCHE DIAGNOSTICS: COMPANY SNAPSHOT
- TABLE 06. ROCHE DIAGNOSTICS: OPERATING SEGMENTS
- TABLE 07. ROCHE DIAGNOSTICS: PRODUCT PORTFOLIO
- TABLE 08. ROCHE DIAGNOSTICS: KEY STRATERGIES
- TABLE 09. ABBOTT LABORATORIES: KEY EXECUTIVES
- TABLE 10. ABBOTT LABORATORIES: COMPANY SNAPSHOT
- TABLE 11. ABBOTT LABORATORIES: OPERATING SEGMENTS
- TABLE 12. ABBOTT LABORATORIES: PRODUCT PORTFOLIO
- TABLE 13. ABBOTT LABORATORIES: KEY STRATERGIES
- TABLE 14. SIEMENS HEALTHINEERS: KEY EXECUTIVES
- TABLE 15. SIEMENS HEALTHINEERS: COMPANY SNAPSHOT
- TABLE 16. SIEMENS HEALTHINEERS: OPERATING SEGMENTS
- TABLE 17. SIEMENS HEALTHINEERS: PRODUCT PORTFOLIO
- TABLE 18. SIEMENS HEALTHINEERS: KEY STRATERGIES
- TABLE 19. NOVA BIOMEDICAL: KEY EXECUTIVES
- TABLE 20. NOVA BIOMEDICAL: COMPANY SNAPSHOT
- TABLE 21. NOVA BIOMEDICAL: OPERATING SEGMENTS
- TABLE 22. NOVA BIOMEDICAL: PRODUCT PORTFOLIO
- TABLE 23. NOVA BIOMEDICAL: KEY STRATERGIES
- TABLE 24. BIONIME: KEY EXECUTIVES
- TABLE 25. BIONIME: COMPANY SNAPSHOT
- TABLE 26. BIONIME: OPERATING SEGMENTS
- TABLE 27. BIONIME: PRODUCT PORTFOLIO
- TABLE 28. BIONIME: KEY STRATERGIES
- TABLE 29. SINOCARE: KEY EXECUTIVES
- TABLE 30. SINOCARE: COMPANY SNAPSHOT
- TABLE 31. SINOCARE: OPERATING SEGMENTS
- TABLE 32. SINOCARE: PRODUCT PORTFOLIO
- TABLE 33. SINOCARE: KEY STRATERGIES
- TABLE 34. MEDTRONIC: KEY EXECUTIVES
- TABLE 35. MEDTRONIC: COMPANY SNAPSHOT
- TABLE 36. MEDTRONIC: OPERATING SEGMENTS
- TABLE 37. MEDTRONIC: PRODUCT PORTFOLIO
- TABLE 38. MEDTRONIC: KEY STRATERGIES
- TABLE 39. LIFESCAN: KEY EXECUTIVES
- TABLE 40. LIFESCAN: COMPANY SNAPSHOT
- TABLE 41. LIFESCAN: OPERATING SEGMENTS
- TABLE 42. LIFESCAN: PRODUCT PORTFOLIO
- TABLE 43. LIFESCAN: KEY STRATERGIES
- TABLE 44. ACON LABORATORIES: KEY EXECUTIVES
- TABLE 45. ACON LABORATORIES: COMPANY SNAPSHOT
- TABLE 46. ACON LABORATORIES: OPERATING SEGMENTS
- TABLE 47. ACON LABORATORIES: PRODUCT PORTFOLIO
- TABLE 48. ACON LABORATORIES: KEY STRATERGIES
- TABLE 49. YPSOMED HOLDING AG: KEY EXECUTIVES
- TABLE 50. YPSOMED HOLDING AG: COMPANY SNAPSHOT
- TABLE 51. YPSOMED HOLDING AG: OPERATING SEGMENTS
- TABLE 52. YPSOMED HOLDING AG: PRODUCT PORTFOLIO
- TABLE 53. YPSOMED HOLDING AG: KEY STRATERGIES
- LIST OF FIGURES
- FIGURE 01. SAUDI ARABIA POINT-OF-CARE GLUCOSE TESTING MARKET, 2022-2032
- FIGURE 02. SEGMENTATION OF SAUDI ARABIA POINT-OF-CARE GLUCOSE TESTING MARKET, 2022-2032
- FIGURE 03. TOP INVESTMENT POCKETS IN SAUDI ARABIA POINT-OF-CARE GLUCOSE TESTING MARKET (2023-2032)
- FIGURE 04. PORTER FIVE-1
- FIGURE 05. PORTER FIVE-2
- FIGURE 06. PORTER FIVE-3
- FIGURE 07. PORTER FIVE-4
- FIGURE 08. PORTER FIVE-5
- FIGURE 09. DRIVERS, RESTRAINTS AND OPPORTUNITIES: SAUDI ARABIA POINT-OF-CARE GLUCOSE TESTING MARKET
- FIGURE 10. SAUDI ARABIA POINT-OF-CARE GLUCOSE TESTING MARKET,BY PRODUCT TYPE, 2022 ($MILLION)
- FIGURE 11. SAUDI ARABIA POINT-OF-CARE GLUCOSE TESTING MARKET,BY APPLICATION, 2022 ($MILLION)
- FIGURE 12. SAUDI ARABIA POINT-OF-CARE GLUCOSE TESTING MARKET,BY END USER, 2022 ($MILLION)
- FIGURE 13. TOP WINNING STRATEGIES, BY YEAR
- FIGURE 14. TOP WINNING STRATEGIES, BY DEVELOPMENT
- FIGURE 15. TOP WINNING STRATEGIES, BY COMPANY
- FIGURE 16. PRODUCT MAPPING OF TOP 10 PLAYERS
- FIGURE 17. COMPETITIVE DASHBOARD
- FIGURE 18. COMPETITIVE HEATMAP: SAUDI ARABIA POINT-OF-CARE GLUCOSE TESTING MARKET
- FIGURE 19. TOP PLAYER POSITIONING, 2022
- FIGURE 20. ROCHE DIAGNOSTICS: NET SALES, 2020-2022* ($MILLION)
- FIGURE 21. ROCHE DIAGNOSTICS: REVENUE SHARE, BY SEGMENT, 2022 (%)
- FIGURE 22. ROCHE DIAGNOSTICS: REVENUE SHARE, BY GEOGRAPHY, 2022 (%)
- FIGURE 23. ABBOTT LABORATORIES: NET SALES, 2020-2022* ($MILLION)
- FIGURE 24. ABBOTT LABORATORIES: REVENUE SHARE, BY SEGMENT, 2022 (%)
- FIGURE 25. ABBOTT LABORATORIES: REVENUE SHARE, BY GEOGRAPHY, 2022 (%)
- FIGURE 26. SIEMENS HEALTHINEERS: NET SALES, 2020-2022* ($MILLION)
- FIGURE 27. SIEMENS HEALTHINEERS: REVENUE SHARE, BY SEGMENT, 2022 (%)
- FIGURE 28. SIEMENS HEALTHINEERS: REVENUE SHARE, BY GEOGRAPHY, 2022 (%)
- FIGURE 29. NOVA BIOMEDICAL: NET SALES, 2020-2022* ($MILLION)
- FIGURE 30. NOVA BIOMEDICAL: REVENUE SHARE, BY SEGMENT, 2022 (%)
- FIGURE 31. NOVA BIOMEDICAL: REVENUE SHARE, BY GEOGRAPHY, 2022 (%)
- FIGURE 32. BIONIME: NET SALES, 2020-2022* ($MILLION)
- FIGURE 33. BIONIME: REVENUE SHARE, BY SEGMENT, 2022 (%)
- FIGURE 34. BIONIME: REVENUE SHARE, BY GEOGRAPHY, 2022 (%)
- FIGURE 35. SINOCARE: NET SALES, 2020-2022* ($MILLION)
- FIGURE 36. SINOCARE: REVENUE SHARE, BY SEGMENT, 2022 (%)
- FIGURE 37. SINOCARE: REVENUE SHARE, BY GEOGRAPHY, 2022 (%)
- FIGURE 38. MEDTRONIC: NET SALES, 2020-2022* ($MILLION)
- FIGURE 39. MEDTRONIC: REVENUE SHARE, BY SEGMENT, 2022 (%)
- FIGURE 40. MEDTRONIC: REVENUE SHARE, BY GEOGRAPHY, 2022 (%)
- FIGURE 41. LIFESCAN: NET SALES, 2020-2022* ($MILLION)
- FIGURE 42. LIFESCAN: REVENUE SHARE, BY SEGMENT, 2022 (%)
- FIGURE 43. LIFESCAN: REVENUE SHARE, BY GEOGRAPHY, 2022 (%)
- FIGURE 44. ACON LABORATORIES: NET SALES, 2020-2022* ($MILLION)
- FIGURE 45. ACON LABORATORIES: REVENUE SHARE, BY SEGMENT, 2022 (%)
- FIGURE 46. ACON LABORATORIES: REVENUE SHARE, BY GEOGRAPHY, 2022 (%)
- FIGURE 47. YPSOMED HOLDING AG: NET SALES, 2020-2022* ($MILLION)
- FIGURE 48. YPSOMED HOLDING AG: REVENUE SHARE, BY SEGMENT, 2022 (%)
- FIGURE 49. YPSOMED HOLDING AG: REVENUE SHARE, BY GEOGRAPHY, 2022 (%)
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.

